|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 次黄嘌呤鸟嘌呤磷酸核糖转移酶研究进展显示文摘次黄嘌呤鸟嘌呤磷酸核糖转移酶(Hypoxanthine-guanine phosphoribosyltransferase,HPRT)是一种细胞质酶,在体内广泛存在,它不仅参与嘌呤碱基的补救合成途径,而且关系到嘌呤类药物的代谢,是调控该类药物药理效应和毒性反应的关键酶。其基因突变可影响酶的活性,不仅可能导致不同临床表现的代谢疾病的发生,而且影响体内嘌呤类药物的代谢。同时,HPRT作为管家基因,是诊断许多疾病的靶点基因。文章概括了HPRT研究的新进展,通过总结国内外研究现状,发现HPRT的研究既推动了嘌呤类药物个体化用药的发展及新药物的研发,又促进了HPRT突变相关遗传代谢疾病的诊断和治疗。 | 丁慧 岳丽杰 杨春兰 | 2013 | 遗传2013，35，8： | 10 |
| 2 | Use of thiopurines in inflammatory bowel disease显示文摘The use of thiopurines as immunosuppression for the treatment of refractory or chronic active inflammatory bowel disease is established for both Crohn's disease and ulcerative colitis.Nevertheless,many questions remain concerning the optimal treatment regimens of azathioprine,6-mercaptopurine and thioguanine.We will briefly summarize dose recommendations,indications for thiopurine therapy and side effects which are relevant in clinical practice.We discuss some currently debated topics,including the combination of azathioprine and allopurinol,switching of thiopurine therapy in case of side effects,the use of azathioprine in pregnancy,the infection risk using thiopurines and the evidence when to stop thiopurines.Excellent reviews have been published on the thiopurine metabolic pathway which will not be discussed here in detail. | Pascal Frei Luc Biedermann Ole Haagen Nielsen Gerhard Rogler | 2013 | World Journal of Gastroenterology2013，19，7： | 4 |
| 3 | Pharmacogenetics implementation in the clinics:information and guidelines for germline variants显示文摘The aim of this work was to supply an overview of the germline Pharmacogenetics that can be already implemented in the oncology clinical practice.An explanation of the three pillars considered necessary for determining which genetic polymorphisms should be used has been provided.These are PharmGKB single nucleotide polymorphism(SNP)-Drug Clinical Annotations with levels of evidence 1 or 2;the genetic information provided in the drug labels by the drug regulatory main agencies(Food and Drug Administration and European Medicines Agency,mainly);and the guidelines elaborated by international expert consortia(mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group).A summary of the relevant SNPs and the recommendations on how to apply their results has also been compiled. | Gladys Olivera Luis Sendra María JoséHerrero Pablo Berlanga Pablo Gargallo Yania Yáñez Andrea Urtasun Jaime Font de Mora Victoria Castel Adela Cañete Salvador FAliño | 2019 | Cancer Drug Resistance2019，2，1： | 1 |
| 4 | 硫唑嘌呤致白细胞减少症临床分析1例显示文摘硫唑嘌呤(Azathioprine,AZA)是一种非特异的免疫抑制剂。用于治疗激素无效或依赖者以及不能使用水杨酸偶氮磺胺吡啶或不能行手术治疗的溃疡性结肠炎患者。约10-28%的患者经历与硫嘌呤治疗相关的不良药物反应,其中最严重的反应是骨髓抑制,通常表现为白细胞减少,其发生率大约为2-5%[1]。本文临床药师就一例口服硫唑嘌呤治疗溃疡性结肠炎引起白细胞减少症的病例做一分析与监护,对替代药物治疗提出建议方案,体现临床药师在临床工作中发挥积极作用。 | 曲若宁 凡炼炼 杨宗辉 | 2019 | 中国实验诊断学2019，0，6： | 0 |
| 5 | 急性淋巴细胞白血病硫嘌呤类药物耐药机制的研究进展显示文摘硫嘌呤类药物是急性淋巴细胞白血病(ALL)治疗缓解期的常用化学治疗药物之一,其在体内需经代谢转化成具有生物活性的巯基鸟嘌呤核苷酸,发挥杀死肿瘤细胞的作用。一旦硫嘌呤类药物在体内代谢通路中的关键酶存在单核苷酸多态性或发生功能突变,肿瘤细胞就会耐受硫嘌呤类药物而产生耐药复发。该文总结了ALL硫嘌呤类药物耐药相关代谢酶突变的研究进展,以期为克服其耐药提供新的思路和策略。 | 方后顺 李慧 杨帆 艾晓杰 周斌兵 | 2016 | 上海交通大学学报(医学版)2016，36，10： | 0 |
| 6 | 非布司他对硫唑嘌呤血药浓度的影响显示文摘目的研究非布司他对硫唑嘌呤血药浓度的影响。方法16只大鼠随机分成硫唑嘌呤组、硫唑嘌呤+非布司他组,每组8只。通过灌胃给药方式给予硫唑嘌呤组大鼠硫唑嘌呤20 mg/(kg·d),硫唑嘌呤+非布司他组大鼠硫唑嘌呤20 mg/(kg·d)+非布司他5 mg/(kg·d),每日1次,连续灌胃给药5 d。在末次给药1 h后取大鼠眼眶后静脉丛血,测定各组大鼠血浆中6-巯基嘌呤的浓度。结果与硫唑嘌呤组相比,硫唑嘌呤+非布司他组大鼠血浆中6-巯基嘌呤的浓度显著升高(P<0.05)。结论非布司他可升高硫唑嘌呤在大鼠体内血药浓度,两药联合使用时建议减少硫唑嘌呤的用量。 | 韩佳 | 2020 | 中国处方药2020，18，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员